1. Home
  2. ADPT vs NATL Comparison

ADPT vs NATL Comparison

Compare ADPT & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$15.41

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo NCR Atleos Corporation

NATL

NCR Atleos Corporation

HOLD

Current Price

$38.67

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
NATL
Founded
2009
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADPT
NATL
Price
$15.41
$38.67
Analyst Decision
Strong Buy
Buy
Analyst Count
10
4
Target Price
$16.60
$42.75
AVG Volume (30 Days)
3.0M
449.1K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.74
Revenue
$252,754,000.00
$4,322,000,000.00
Revenue This Year
$50.81
$2.83
Revenue Next Year
$1.17
$3.96
P/E Ratio
N/A
$22.24
Revenue Growth
42.57
0.63
52 Week Low
$5.81
$22.30
52 Week High
$20.76
$42.23

Technical Indicators

Market Signals
Indicator
ADPT
NATL
Relative Strength Index (RSI) 44.33 62.03
Support Level $14.58 $36.12
Resistance Level $16.26 $37.61
Average True Range (ATR) 1.13 0.94
MACD -0.36 0.32
Stochastic Oscillator 13.75 86.58

Price Performance

Historical Comparison
ADPT
NATL

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: